A trial of a new HIV latency-reversing drug
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new type of medicine that aims to wake up HIV hiding in your body's cells by targeting a viral protein called Tat. The goal is to help find a way to clear the virus completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be HIV-positive and taking antiretroviral therapy (ART).
- Your HIV viral load must have been undetectable for at least 12 months.
- You must have had a lowest CD4 count below 200 cells per microliter at some point in the past.
- You cannot have had cancer in the past 5 years or be on immunosuppressive drugs.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects blood samples from people living with HIV to study dormant (inactive) HIV cells in the lab. The goal is to better understand how to target these hidden cells as part of an eventual cure.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.